A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

NCT01636843 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

298

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammation
Rheumatoid Arthritis

Interventions

DRUG: NNC0109-0012
DRUG: placebo

Sponsor

Novo Nordisk A/S